Company news

eXoZymes Inc. news in 2026

eXoZymes Inc.'s news releases, calls and decks from 2026, newest first.

View company

eXoZymes CEO to Discuss Commercialization, Key Milestones, and Potential Catalysts in Fireside Chat with Water Tower Research

October 21, 2026

eXoZymes Selects Curia as Commercial-Scale Manufacturing Partner for NCT

September 8, 2026

eXoZymes Reports Second Quarter 2026 Results and Provides Business Update at 5PM ET Today

August 20, 2026

eXoZymes Selected for DoE's Genesis Mission to Advance AI-Powered Digital Twins for Cell-Free Biomanufacturing

July 22, 2026

eXoZymes Awarded $2 Million NIH Grant to Advance Cannabinoid Analogs for Drug Discovery

June 23, 2026

EXoZymes Inc. Announces Closing of $6 Million Public Offering

June 17, 2026

eXoZymes Inc. Announces Pricing of Public Offering of Common Stock and Warrants

June 8, 2026

eXoZymes Announces Graduation from Shell GameChanger(TM) Accelerator Powered by NLR (GCxN) Program

May 6, 2026

eXoZymes Provides Fourth Quarter and Full Year 2025 Update

March 31, 2026

eXoZymes to Host Fourth Quarter and Full Year 2025 Results Conference Call on Tuesday March 31, 2026

March 25, 2026

Successful Pilot Scale Run with Cayman Chemical Validates eXoZymes' Technology and Scalability

March 18, 2026

eXoZymes' CCO Damien Perriman to Present a NCT Solution at Next Week's MISTA Symposium

March 12, 2026

With Refreshed Brand eXoZymes Sharpens Pharmaceutical Focus to Drive Platform Leverage and Long-Term Value Creation

February 10, 2026

eXoZymes Advancing Commercial Readiness With Profound Production Metrics on Initial NCT Pilot Run

January 29, 2026

Calls in 2026

Decks in 2026